mead ethanolamide: an eicosanoid; an agonist for the central and peripheral cannabinoid receptors [MeSH]
Mead acid-EA : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 16061185 |
| SCHEMBL ID | 14864037 |
| CHEBI ID | 165588 |
| MeSH ID | M0250956 |
| Synonym |
|---|
| mead acid-ea |
| LMFA08040037 |
| n-(5z,8z,11z-eicosatrienoyl)-ethanolamine |
| BSPBIO_001414 |
| IDI1_033884 |
| NCGC00161308-01 |
| NCGC00161308-02 |
| NCGC00161308-03 |
| HMS1989G16 |
| (5z,8z,11z)-n-(2-hydroxyethyl)icosa-5,8,11-trienamide |
| CHEBI:165588 |
| mead ethanolamide |
| BML2-C02 |
| HMS1791G16 |
| HMS1361G16 |
| 169232-04-6 |
| BRD-K09764130-001-01-8 |
| FA027 |
| SCHEMBL14864037 |
| n-(5z,8z,11z-eicosatrienoyl)ethanolamine |
| YKGQBEGMUSSPFY-YOILPLPUSA-N |
| 5(z),8(z),11(z)-eicosatrienoic acid ethanolamide |
| n-(2-hydroxyethyl)-5z,8z,11z-eicosatrienamide |
| 5,8,11-eicosatrienamide, n-(2-hydroxyethyl)-, (5z,8z,11z)- |
| HMS3402G16 |
| HMS3649F21 |
| SR-01000946656-1 |
| sr-01000946656 |
| PD020547 |
| DTXSID901348030 |
| (5z,8z,11z)-n-(2-hydroxyethyl)-5,8,11-icosatrienamide |
| Class | Description |
|---|---|
| N-acylethanolamine 20:3 | A N-(long-chain-acyl)ethanolamine in which the acyl group contains 20 carbons and 3 double bonds. |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 ISSN: 1872-9096 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 ISSN: 1464-3405 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| homo-gamma-linolenylethanolamide | N-acylethanolamine 20:3 | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cyclohexanol | cyclohexanols; secondary alcohol | solvent | 1995 | 1995 | 29.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |
| arachidonic acid | icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid | Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite | 1995 | 1995 | 29.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |
| 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol | alkylbenzene; ring assembly | 1995 | 1995 | 29.0 | high | 0 | 0 | 1 | 0 | 0 | 0 | ||
| 8,11,14-eicosatrienoic acid | fatty acid 20:3; long-chain fatty acid | fungal metabolite; human metabolite; nutraceutical | 1995 | 1995 | 29.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | |
| anandamide | endocannabinoid; N-acylethanolamine 20:4 | human blood serum metabolite; neurotransmitter; vasodilator agent | 1995 | 1995 | 29.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congenital Zika Syndrome | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Disease Models, Animal | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Encephalitis, Polio | 0 | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Poliomyelitis | 0 | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Zika Virus Infection | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |